Darunavir

Active ingredient: Darunavir Propylene Glycolate

In short: Darunavir tablets, co-administered with ritonavir (darunavir/ritonavir), in combination with other antiretroviral agents, is indicated for the treatment of human immunodeficiency virus (HIV-1) infection in adult and pediatric patients 3 years of age and older .

Forms & strengths600 mg: orange colored, oval shaped, biconvex, film-coated tablets debossed with ‘D’ on one side and ‘600’ on another side. 800 mg: dark red colored, oval shaped, biconvex, film-coated tablets debossed with ‘D’ on one side and ‘800’ on another side.
LabelAurobindo Pharma Limited
Label updatedNov 16, 2026

What is Darunavir used for?

Darunavir tablets, co-administered with ritonavir (darunavir/ritonavir), in combination with other antiretroviral agents, is indicated for the treatment of human immunodeficiency virus (HIV-1) infection in adult and pediatric patients 3 years of age and older .

Darunavir dosage

In treatment-experienced patients, treatment history, genotypic and/or phenotypic testing is recommended to assess drug susceptibility of the HIV-1 virus . Refer to

Dosage and Administration (2.3), (2.4) and (2.5) for dosing recommendations.

Appropriate laboratory testing such as serum liver biochemistries should be conducted prior to initiating therapy with darunavir/ritonavir .

Patients with underlying chronic hepatitis, cirrhosis, or in patients who have pre-treatment elevations of transaminases should be monitored for elevation in serum liver biochemistries, especially during the first several months of darunavir/ritonavir treatment .

Darunavir tablets must be co-administered with ritonavir to exert its therapeutic effect. Failure to correctly co-administer darunavir tablets with ritonavir will result in plasma levels of darunavir that will be insufficient to achieve the desired antiviral effect and will alter some drug interactions.

Patients who have difficulty swallowing darunavir tablets can use the 100 mg per mL darunavir oral suspension.

Treatment-Naïve Adult Patients

The recommended oral dose of darunavir is 800 mg (one 800 mg tablet or 8 mL of the oral suspension) taken with ritonavir 100 mg (one 100 mg tablet or capsule or 1.25 mL of a 80 mg per mL ritonavir oral solution) once daily and with food. An 8 mL darunavir oral suspension dose should be taken as two 4 mL administrations with the included oral dosing syringe.

Treatment-Experienced Adult Patients

The recommended oral dosage for treatment-experienced adult patients is summarized in Table 1.

Baseline genotypic testing is recommended for dose selection. However, when genotypic testing is not feasible, darunavir tablets 600 mg taken with ritonavir 100 mg twice daily is recommended.

Table 1: Recommended darunavir/ritonavir Dosage in Treatment-Experienced Adult Patients

Formulation and Recommended Dosing

Baseline Resistance | Darunavir tablets with ritonavir tablets or capsule | Darunavir oral suspension (100 mg/mL) with ritonavir oral solution (80 mg/mL)

With no darunavir resistance associated substitutionsa | One 800 mg darunavir tablet with one 100 mg ritonavir tablet/capsule, taken once daily with food | 8 mLb darunavir oral suspension with 1.25 mL ritonavir oral solution, taken once daily with food

With at least one darunavir resistance associated substitutionsa, or with no baseline resistance information | One 600 mg darunavir tablet with one 100 mg ritonavir tablet/capsule, taken twice daily with food | 6 mL darunavir oral suspension with 1.25 mL ritonavir oral solution, taken twice daily with food

aV11I, V32I, L33F, I47V, I50V, I54L, I54M, T74P, L76V, I84V and L89V

bAn 8 mL darunavir dose should be taken as two 4 mL administrations with the included oral dosing syringe. …

How to take Darunavir — instructions & advice from the label

Advise the patient to read the FDA-approved patient labeling (Patient Information).

Instructions for Use

Advise patients to take darunavir and ritonavir with food every day on a regular dosing schedule, as missed doses can result in development of resistance. Darunavir must always be used with ritonavir in combination with other antiretroviral drugs. Advise patients not to alter the dose of either darunavir or ritonavir, discontinue ritonavir, or discontinue therapy with darunavir without consulting their physician .

Hepatotoxicity

Inform patients that drug-induced hepatitis (e.g., acute hepatitis, cytolytic hepatitis) has been reported with darunavir co-administered with 100 mg of ritonavir. Advise patients about the signs and symptoms of liver problems .

Severe Skin Reactions

Inform patients that skin reactions ranging from mild to severe, including Stevens-Johnson syndrome, drug rash with eosinophilia and systemic symptoms, and toxic epidermal necrolysis, have been reported with darunavir co-administered with 100 mg of ritonavir. Advise patients to discontinue darunavir/ritonavir immediately if signs or symptoms of severe skin reactions develop. …

Warnings & precautions

Do not take this medicine if: Co-administration of darunavir/ritonavir is contraindicated with drugs that are highly dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with serious and/or life-threatening events (narrow therapeutic index). Examples of these drugs and other contraindicated drugs (which may lead to reduced efficacy of darunavir) are listed below . Due to the need for co-administration of darunavir with ritonavir, please refer to ritonavir prescribing information for a description of ritonavir contraindications.

Alpha 1-adrenoreceptor antagonist: alfuzosin

Anti-gout: colchicine, in patients with renal and/or hepatic impairment

Antimycobacterial: rifampin

Antipsychotics: lurasidone, pimozide

Cardiac Disorders: dronedarone, ivabradine, ranolazine

Ergot derivatives, e.g., dihydroergotamine, ergotamine, methylergonovine

Herbal product: St. John’s wort (Hypericum perforatum)

Hepatitis C direct acting antiviral: elbasvir/grazoprevir

Lipid modifying agents: lomitapide, lovastatin, simvastatin

Opioid Antagonist: naloxegol

PDE-5 inhibitor: sildenafil when used for treatment of pulmonary arterial hypertension

Sedatives/hypnotics: orally administered midazolam, triazolam

Darunavir must be co-administered with ritonavir and food to achieve the desired antiviral effect. Failure to administer darunavir with ritonavir and food may result in a loss of efficacy of darunavir.

Please refer to ritonavir prescribing information for additional information on precautionary measures.

Drug-induced hepatitis (e.g., acute hepatitis, cytolytic hepatitis) has been reported with darunavir/ritonavir. During the clinical development program (N=3063), hepatitis was reported in 0.5% of patients receiving combination therapy with darunavir/ritonavir. …

Darunavir side effects

The following adverse reactions are discussed in other sections of labeling:

Hepatotoxicity

Severe Skin Reactions

Diabetes Mellitus/Hyperglycemia

Fat Redistribution

Immune Reconstitution Syndrome

Hemophilia

Due to the need for co-administration of darunavir with ritonavir, please refer to ritonavir prescribing information for ritonavir-associated adverse reactions.

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.

Treatment Naïve-Adults: TMC114-C211

The safety assessment is based on all safety data from the Phase 3 trial TMC114-C211 comparing darunavir/ritonavir 800/100 mg once daily versus lopinavir/ritonavir 800/200 mg per day in 689 antiretroviral treatment-naïve HIV-1-infected adult subjects. The total mean exposure for subjects in the darunavir/ritonavir 800/100 mg once daily arm and in the lopinavir/ritonavir 800/200 mg per day arm was 162.5 and 153.5 weeks, respectively.

The majority of the adverse drug reactions (ADRs) reported during treatment with darunavir/ritonavir 800/100 mg once daily were mild in severity. The most common clinical ADRs to darunavir/ritonavir 800/100 mg once daily (greater than or equal to 5%) of at least moderate intensity (greater than or equal to Grade 2) were diarrhea, headache, abdominal pain and rash. …

Drug interactions

Darunavir co-administered with ritonavir is an inhibitor of CYP3A, CYP2D6, and P-gp. Co-administration of darunavir and ritonavir with drugs that are primarily metabolized by CYP3A and CYP2D6 or are transported by P-gp may result in increased plasma concentrations of such drugs, which could increase or prolong their therapeutic effect and adverse events. Darunavir co-administered with ritonavir with drugs that have active metabolite(s) formed by CYP3A may result in reduced plasma concentrations of these active metabolite(s), potentially leading to loss of their therapeutic effect .

Darunavir and ritonavir are metabolized by CYP3A. In vitro data indicate that darunavir may be a P-gp substrate. Drugs that induce CYP3A activity would be expected to increase the clearance of darunavir and ritonavir, resulting in lowered plasma concentrations of darunavir and ritonavir. Co-administration of darunavir and ritonavir and other drugs that inhibit CYP3A, or P-gp may decrease the clearance of darunavir and ritonavir and may result in increased plasma concentrations of darunavir and ritonavir .

Table 10 provides dosing recommendations as a result of drug interactions with darunavir/ritonavir. …

About this medicine

Darunavir is an inhibitor of the human immunodeficiency virus (HIV-1) protease.

Darunavir tablets contain the active ingredient darunavir, (present as darunavir propylene glycolate) which has the following chemical name: [(1S,2R)-3-[[(4-aminophenyl)sulfonyl](2-methyl-propyl)amino]-2-hydroxy-1-(phenylmethyl)- propyl]carbamic acid (3R,3aS,6aR)-hexahydro-furo[2,3-b]furan-3-yl ester. 1,2-propanediol solvate. Its molecular formula is C27H37N3O7S•C3H8O2 and its molecular weight is 623.73. Darunavir propylene glycolate has the following structural formula:

Darunavir propylene glycolate is a white to off-white, slightly hygroscopic powder with a solubility of approximately 0.21 mg per mL in water at 37°C.

Darunavir 600 mg tablets are available as orange colored, oval shaped, biconvex, film-coated tablets for oral administration. Each 600 mg tablet contains darunavir 600 mg (present as darunavir propylene glycolate).

Darunavir 800 mg tablets are available as dark red colored, oval shaped, biconvex, film-coated tablets for oral administration. …

Disclaimer: This page is for general information only and is not medical advice. It is a condensed summary of the official FDA-approved label — it does not replace the full prescribing information or the advice of your doctor or pharmacist. Always follow your prescriber's instructions and read the medication guide that comes with your medicine.

Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 88910ad0-6dc3-4a47-8a6b-5c6ee79f2a93. Read the full official label on DailyMed.

Related medicines

Amoxicillin Azithromycin Doxycycline Amoxicillin and Clavulanate Cephalexin Valacyclovir Sulfamethoxazole and Trimethoprim Nitrofurantoin